Photo generated from ascopubs.org
Jun 9, 2024, 14:57
No survival advantage for first-line liposomal irinotecan patients with pancreatic adenocarcinoma
Mark Lewis shared on X:
“Important abstract (GIANT, or EA2186) from ASCO24 which does NOT show a survival advantage for first-line liposomal irinotecan (vs. gemcitabine/Abraxane) in elderly (70 or older, median = 77) patients with pancreatic adenocarcinoma.”
Read further
Source: Mark Lewis/X
Mark Lewis is the Director of Gastrointestinal Oncology at Intermountain Healthcare in Utah, the Co-Chair of adolescent & young adult (AYA) oncology in the SWOG cooperative group and the Vice President of American Multiple Endocrine Neoplasia Support. Dr. Lewis is also a well-known patient advocate and social media influencer.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 21, 2024, 19:39
Dec 21, 2024, 19:21
Dec 21, 2024, 19:19
Dec 21, 2024, 19:18
Dec 21, 2024, 18:59
Dec 21, 2024, 18:57
Dec 21, 2024, 18:54